In the penultimate week before the end-of-year recess, Congress raced to provide the drug industry—and the rest of corporate America—a massive tax cut, with breaks for investors, too. Racing to finish their own end-of-year budgets, perhaps, investors poured hundreds of millions... Read more »
Mark Skinner, the former longtime president of the World Federation of Hemophilia, has had the blood disease on his mind his entire life.
He doesn’t have a choice.
Skinner, 57, was born with a severe form of hemophilia A, meaning he... Read more »
[Updated 12/12/17, 5:51 pm. See below.] Global automotive technology supplier Aptiv is planting a bigger flag in Boston.
On Tuesday, the England-based company announced plans to open a new technology office in Boston’s Seaport neighborhood. The space will also... Read more »
[Updated, 12/13/17, 1:50 p.m. ET. See below.] The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements. No surprise, there’s a lot... Read more »
Eli Lilly is dropping plans to seek expanded FDA approval for ramucirumab (Cyramza) in stomach cancer after the drug missed a key goal in a late-stage study.
The Lilly (NYSE: LLY) drug is already approved, in combination with the drug... Read more »
Whether you think self-driving cars are the stuff of science fiction or a potentially paradigm-shifting new form of transportation, autonomous vehicles are coming—and the companies developing them are spending big money to make it happen.
A few years ago, industry analysts... Read more »
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too.
The FDA will... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
[Corrected, 12/11/17, 1 p.m. ET. See below.] On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease,... Read more »
Author, investor, and AOL co-founder Steve Case today announced a new $150 million venture fund aimed at pumping investment capital into tech companies in so-called flyover states. Contributing to the fund is an impressive group of some of the most successful... Read more »
Many of biotech’s biggest stories in 2017 followed the highly anticipated data from clinical studies. There were monumental successes, like the first-ever approval of a genetically modified living cell therapy, the first FDA application for a gene therapy or a... Read more »
A pair of migraine drugs made a splash in biotech news this week with published data suggesting that they can reduce the frequency of headaches.
These drugs still await an FDA decision, and their impact on patients over the long term... Read more »
If Wednesday’s hearing for Health and Human Services Secretary Nominee Alex Azar is any indication, reining in drug prices and insurance premiums are the policy priorities that will guide Congress’s interaction with the department under a new leader.
For the better... Read more »